Craig S. Glazer

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis

Imre Noth, Kevin J. Anstrom, Sara B. Calvert et al. · American Journal of Respiratory and Critical Care Medicine · 2012 · 461 citations · Full text

Telomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations

Alberto Diaz de Leon, Jennifer T. Cronkhite, Anna-Luise A. Katzenstein et al. · PLoS ONE · 2010 · 369 citations · Full text

Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive

Chad A. Newton, Kiran Batra, José Torrealba et al. · European Respiratory Journal · 2016 · 365 citations · Full text

Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation

Bridget Stuart, Joyce Lee, Julia Kozlitina et al. · The Lancet Respiratory Medicine · 2014 · 297 citations · Full text

Fibrosis, Idiopathic Pulmonary Fibrosis, Telomere Length +5